Search

Displaying results 2351 - 2360 of 10000 in total
  1. Drug

    Nickel sulfate

    go.drugbank.com/drugs/DB14180
    Approved

    Nickel sulfate is used in allergenic testing.

    Categories: Compounds used in a research, industrial, or household settingSynonyms: nickel(II) sulfate
  2. Drug

    Zavegepant

    go.drugbank.com/drugs/DB15688
    ApprovedInvestigational

    [L45505] CGRP is released from sensory nerves and acts as a strong vasodilator, and thanks to these properties, it is involved in pain pathways. … Zavegepant is a third-generation CGRP receptor antagonist that is small in size and highly soluble. Due to its pharmacological properties, it can be administered intranasally.

    Synonyms: 1-piperidinecarboxamide, 4-(1,2-dihydro-2-oxo-3-quinolinyl)-n-((1r)-1-((7-methyl-1h-indazol-5-yl)methyl)-2-(4-(1-methyl-4-piperidinyl)-1-piperazinyl)-2-oxoethyl)-
  3. Drug

    Escitalopram

    go.drugbank.com/drugs/DB01175
    ApprovedInvestigational

    Escitalopram is a selective serotonin re-uptake inhibitor (SSRI) and the S-enantiomer of racemic [citalopram]. … [A185420] It is used to restore serotonergic function in the treatment of depression and anxiety.

    Categories: Monoamine Oxidase A SubstratesProducts: Escitalopram-GN 10 mg Filmtabletten, Escitalopram-GN 20 mg Filmtabletten
  4. Drug

    Oteracil

    go.drugbank.com/drugs/DB03209
    ApprovedInvestigational

    The main active ingredient in Teysuno is [DB09256], a pro-drug of [DB00544] (5-FU), which is a cytotoxic anti-metabolite drug that acts on rapidly dividing cancer cells. … Approved by the European Medicines Agency (EMA) in March 2011, Oteracil is available in combination with [DB09257] and [DB09256] within the commercially available product "Teysuno".

  5. Drug

    Rimegepant

    go.drugbank.com/drugs/DB12457
    ApprovedInvestigational

    [L11028] It received FDA approval on February 27, 2020 for the acute treatment migraine headache,[L11974] and was subsequently approved by the European Commission in April 2022 for both the treatment and … safer for use in patients with contraindications to standard therapy.

  6. Drug

    Vandetanib

    go.drugbank.com/drugs/DB05294
    ApprovedInvestigational

    Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types. … On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients.

    Categories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic IndexSynonyms: N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine, N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine
  7. Drug

    Concizumab

    go.drugbank.com/drugs/DB12820
    ApprovedInvestigational

    [L52043] Concizumab-mtci (Alhemo) was approved by the FDA in December 2024 for use in patients with hemophilia A or B with inhibitors. … [A264883,A264878] In patients with hemophilia A or B - characterized by deficiencies in clotting factors VIII or IX, respectively - the traditional treatment involves replacement of the missing clotting

  8. Drug

    Rubidium Rb-82

    go.drugbank.com/drugs/DB09479
    ApprovedInvestigational

    Rubidium chloride Rb-82 injection is a sterile nonpyrogenic solutions of rubidium Rb 82 chloride. … It is indicated for Positron Emission Tomography (PET) imaging of the myocardium under rest or pharmacologic stress conditions to evaluate regional myocardial perfusion in adult patients with suspected

  9. Drug

    Probenecid

    go.drugbank.com/drugs/DB01032
    ApprovedInvestigational

    It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. … Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.

    Categories: Compounds used in a research, industrial, or household setting, Preparations With No Effect on Uric Acid MetabolismSynonyms: 4-(N,N-Dipropylsulfamoyl)benzoesäure, 4-(Di-n-propylsulfamoyl)benzoesäure
  10. Drug

    Pomalidomide

    go.drugbank.com/drugs/DB08910
    ApprovedInvestigational

    Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.

    Categories: P-glycoprotein substrates with a Narrow Therapeutic Index, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index